Low glomerular filtration rate is a risk factor for ribavirin-associated anaemia in old patients with chronic hepatitis C

Journal of Viral Hepatitis

Volumn 20, Issue 4, 2013, Pages

  Borroni, G ^a   Cazzaniga, M ^b   Andreoletti, M ^c   Ceriani, R ^d   Guerzoni, P ^e   Omazzi, B ^f   Pich, M G L ^d   Prada, A ^f   Spinzi, G ^g   Terreni, N ^g   Salerno, F ^b  

^a ASL Provincia di Milano 1   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c A MANZONI HOSPITAL   (Italy)

^d HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^e OSPEDALE DI CIRCOLO   (Italy)

^f RHO HOSPITAL   (Italy)

^g VALDUCE HOSPITAL   (Italy)

Author keywords

age; anaemia; chronic hepatitis C; renal function; ribavirin; treatment

Indexed keywords

CREATININE; HEMOGLOBIN; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ADULT; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; BODY WEIGHT; CLINICAL ASSESSMENT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; GENOTYPE; GLOMERULUS FILTRATION RATE; HEPATITIS C; HIGH RISK PATIENT; HUMAN; KIDNEY FUNCTION; LEUKOCYTE COUNT; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANEMIA; ANTIVIRAL AGENTS; DRUG TOXICITY; FEMALE; GLOMERULAR FILTRATION RATE; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; MALE; MIDDLE AGED; RIBAVIRIN; RISK FACTORS;

EID: 84875227887     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12015     Document Type: Article

References (28)

1. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ,. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144: 705-714.
2. McHutchinson JG, Bacon BR,. Chronic hepatitis C: an age wave of disease burden. Am J Manag Care 2005; 11: S286-S295.
3. Guadagnino V, Stroffolini T, Rapicetta M, et al,. Prevalence, risk factors, and genotype distribution of hepatitis C virus infection in the general population: a community-based survey in southern Italy. Hepatology 1997; 26: 1006-1011.
4. Sagnelli E, Stroffolini T, Mele A, et al,. The importance of HCV on the burden of chronic liver disease in Italy: a multicenter prevalence study of 9,997 cases. J Med Virol 2005; 75: 522-527.
5. Manns MP, McHutchinson JG, Gordon SC, et al,. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358: 958-965.
6. Fried MW, Shiffman ML, Reddy KR, et al,. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982.
7. Hadziyannis SJ, Sette Jr H, Morgan TR, et al,. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-355.
8. Reddy KJ, Messinger D, Popescu M, Hadziyannis SJ,. Peginterferon alfa-2a (40kDa) and ribavirin: comparable rates of sustained virological response in sub-sets of older and younger HCV genotype 1 patients. J Viral Hepat 2009; 16: 724-731.
9. Flamm SL, Jacobson IM, Brown R, et al,. Pegylated interferon alfa 2b + ribavirin are equally efficacious and well tolerated in interferon therapy in elderly patients with chronic hepatitis C patients >65 years old in comparison to other age groups: subanalysis of a randomized, controlled study (WIN-R trial). Hepatology 2006; 44 (Suppl.1): 315A-316A.
10. Antonucci G, Longo MA, Angeletti C, et al,. The effect of age on response to therapy with peginterferon alpha plus ribavirin in a cohort of patients with chronic HCV hepatitis including subjects older than 65 yr. Am J Gastroenterol 2007; 102: 1383-1391.
11. Lindahl K, Schvarcz R, Bruchfeld A, Ståhle L,. Evidence that plasma concentration rather than dose per kilogram body weight predicts ribavirin-induced anaemia. J Viral Hepat 2004; 11: 84-87.
12. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D,. A more accurate method to estimate glomerular filtration rate from serum creatine: a new prediction equation. Ann Intern Med 1999; 130: 461-470.
13. Nomura H, Tanimoto H, Kajiwara E, et al,. Factors contributing to ribavirin-induced anemia. J Gastroenterol Hepatol 2004; 19: 1312-1317.
14. Takaki S, Tsubota A, Hosaka T, et al,. Factors contributing to ribavirin dose reduction due to anemia during interferon alfa2b and ribavirin combination therapy for chronic hepatitis C. J Gastroenterol 2004; 39: 668-673.
15. Van Vlierberghe H, Delanghe JR, De Vos M, Leroux-Roel G,; BASL Steering Committee. Factors influencing ribavirin-induced hemolysis. J Hepatol 2001; 34: 911-916.
16. Oze T, Hiramatsu N, Kurashige N, et al,. Early decline of hemoglobin correlates with progression of ribavirin-induced hemolytic anemia during interferon plus ribavirin combination therapy in patients with chronic hepatitis C. J Gastroenterol 2006; 41: 862-872.
17. De Franceschi L, Fattovich G, Turrini F, et al,. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. Hepatology 2000; 31: 997-1004.
18. Uchida M, Hamada A, Yamasaki M, Fujiyama S, Sasaki Y, Saito H,. Assessment of adverse reactions and pharmacokinetics of ribavirin in combination with interferon alpha-2b in patients with chronic hepatitis C. Drug Metab Pharmacokinet 2004; 19: 438-443.
19. Bruchfeld A, Lindahl K, Schvarcz R, Ståhle L,. Dosage of ribavirin in patients with hepatitis C should be based on renal function: a population pharmacokinetic analysis. Ther Drug Monit 2002; 24: 701-708.
20. Sulkowski MS, Wasserman R, Brooks L, Ball L, Gish R,. Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection. J Viral Hepat 2004; 11: 243-250.
21. Bruchfeld A, Lindahl K, Ståhle L, Söderberg M, Schvarcz R,. Interferon and ribavirin treatment in patients with hepatitis C-associated renal disease and renal insufficiency. Nephrol Dial Transplant 2003; 18: 1573-1580.
22. Sulkowski MS, Shiffman ML, Afdhal NH, et al,. Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate. Gastroenterology 2010; 139: 1602-1611.
23. Sievert W, Dore GJ, McCaughan GW, et al,. Virological response is associated with decline in hemoglobin concentration during pegylated interferon and ribavirin therapy in hepatitis C virus genotype 1. Hepatology 2011; 53: 1109-1117.
24. Stevens LA, Coresh J, Greene T, Levey AS,. Assessing kidney function measured and estimated glomerular filtration rate. N Engl J Med 2006; 354: 2473-2483.
25. Cholongitas E, Shusang V, Marelli L, et al,. Review article: renal function assessment in cirrhosis-difficulties and alternative measurements. Aliment Pharmacol Ther 2007; 26: 969-978.
26. McHutchison JG, Everson GT, Gordon SC, et al,. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009; 360: 1827-1838.
27. Kwo P, Lawitz EJ, McCone J, et al,. HCV SPRINT-1 final results: SVR 24 from a phase II study of boceprevir plus peginterferon alfa-2b/ribavirin in treatment-naive subjects with genotype 1 chronic hepatitis C. J Hepatol 2009; 50: S4.
28. Stenvinkel P,. Chronic kidney disease: a public health priority and harbinger of premature cardiovascular disease. J Intern Med 2010; 268: 456-467.